Explore

TrendlineTrendline
Humana Exceeds Q3 Earnings and Revenue Forecasts, Boosts Full-Year Guidance

Humana Exceeds Q3 Earnings and Revenue Forecasts, Boosts Full-Year Guidance

Humana Exceeds Q3 Earnings and Revenue Forecasts, Boosts Full-Year Guidance
TrendlineTrendline
Prudential Financial Reports Mixed Q3 2026 Results, Exceeding EPS Estimates but Missing Revenue Targets

Prudential Financial Reports Mixed Q3 2026 Results, Exceeding EPS Estimates but Missing Revenue Targets

Prudential Financial Reports Mixed Q3 2026 Results, Exceeding EPS Estimates but Missing Revenue Targets
TrendlineTrendline
EOG Resources Reports Record Q3 2026 Volumes and 8% Dividend Increase

EOG Resources Reports Record Q3 2026 Volumes and 8% Dividend Increase

EOG Resources Reports Record Q3 2026 Volumes and 8% Dividend Increase
TrendlineTrendline
Gold Royalty Corp. Reports Record Q3 and Nine-Month Results, Driven by Strong Cash Flow and Earnings Growth

Gold Royalty Corp. Reports Record Q3 and Nine-Month Results, Driven by Strong Cash Flow and Earnings Growth

Gold Royalty Corp. Reports Record Q3 and Nine-Month Results, Driven by Strong Cash Flow and Earnings Growth
TrendlineTrendline
STMicroelectronics Reports Strong Q3 FY 2026 Results Driven by AI Data Center and Satellite Communications Demand

STMicroelectronics Reports Strong Q3 FY 2026 Results Driven by AI Data Center and Satellite Communications Demand

STMicroelectronics Reports Strong Q3 FY 2026 Results Driven by AI Data Center and Satellite Communications Demand
TrendlineTrendline
Bob's Discount Furniture Reports Strong Q3 2026 Financial Results and Reaffirms Full-Year Outlook

Bob's Discount Furniture Reports Strong Q3 2026 Financial Results and Reaffirms Full-Year Outlook

Bob's Discount Furniture Reports Strong Q3 2026 Financial Results and Reaffirms Full-Year Outlook
ReutersReuters
Novo hikes outlook again as it speeds up Wegovy pill rollout

Novo hikes outlook again as it speeds up Wegovy pill rollout

By Patrick Wingrove and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Nov 4 (Reuters) - Obesity drugmaker Novo Nordisk raised its 2026 outlook for the third time this year on Wednesday as quarterly sales of its Wegovy pill beat forecasts, bolstering the Danish firm's efforts to recover ground lost to
TrendlineTrendline
GXO Logistics Reports Strong Q3 2026 Results, Driving 20.9% Stock Advance

GXO Logistics Reports Strong Q3 2026 Results, Driving 20.9% Stock Advance

GXO Logistics Reports Strong Q3 2026 Results, Driving 20.9% Stock Advance
TrendlineTrendline
Gulfport Energy Corporation Reports Strong Third Quarter 2026 Financial Results

Gulfport Energy Corporation Reports Strong Third Quarter 2026 Financial Results

Gulfport Energy Corporation Reports Strong Third Quarter 2026 Financial Results
TrendlineTrendline
Clayton, Dubilier Rice Explores $40 Billion Take-Private Deal for Global Payments

Clayton, Dubilier Rice Explores $40 Billion Take-Private Deal for Global Payments

Clayton, Dubilier Rice Explores $40 Billion Take-Private Deal for Global Payments
TrendlineTrendline
Indie Semiconductor Reports Strong Q3 2026 Results, Projects Continued Revenue Growth

Indie Semiconductor Reports Strong Q3 2026 Results, Projects Continued Revenue Growth

Indie Semiconductor Reports Strong Q3 2026 Results, Projects Continued Revenue Growth
TrendlineTrendline
Marriott Vacations Worldwide Misses Q3 2026 Revenue Estimates Despite Year-Over-Year Growth

Marriott Vacations Worldwide Misses Q3 2026 Revenue Estimates Despite Year-Over-Year Growth

Marriott Vacations Worldwide Misses Q3 2026 Revenue Estimates Despite Year-Over-Year Growth